Chyka Peter A, Erdman Andrew R, Manoguerra Anthony S, Christianson Gwenn, Booze Lisa L, Nelson Lewis S, Woolf Alan D, Cobaugh Daniel J, Caravati E Martin, Scharman Elizabeth J, Troutman William G
American Association of Poison Control Centers, Washington, District of Columbia, USA.
Clin Toxicol (Phila). 2007 Sep;45(6):662-77. doi: 10.1080/15563650701606443.
The objective of this guideline is to assist poison center personnel in the appropriate out-of-hospital triage and initial out-of-hospital management of patients with a suspected ingestion of dextromethorphan by 1) describing the process by which an ingestion of dextromethorphan might be managed, 2) identifying the key decision elements in managing cases of dextromethorphan ingestion, 3) providing clear and practical recommendations that reflect the current state of knowledge, and 4) identifying needs for research. This guideline applies to the ingestion of dextromethorphan alone. Co-ingestion of additional substances could require different referral and management recommendations depending on the combined toxicities of the substances. This guideline is based on an assessment of current scientific and clinical information. The expert consensus panel recognizes that specific patient care decisions might be at variance with this guideline and are the prerogative of the patient and the health professionals providing care, considering all of the circumstances involved. This guideline does not substitute for clinical judgment. The grade of recommendation is in parentheses. 1) All patients with suicidal intent, intentional abuse, or in cases in which a malicious intent is suspected (e.g., child abuse or neglect) should be referred to an emergency department (Grade D). 2) Patients who exhibit more than mild effects (e.g., infrequent vomiting or somnolence [lightly sedated and arousable with speaking voice or light touch]) after an acute dextromethorphan ingestion should be referred to an emergency department (Grade C). 3) Patients who have ingested 5-7.5 mg/kg should receive poison center-initiated follow-up approximately every 2 hours for up to 4 hours after ingestion. Refer to an emergency department if more than mild symptoms develop (Grade D). 4) Patients who have ingested more than 7.5 mg/kg should be referred to an emergency department for evaluation (Grade C). 5) If the patient is taking other medications likely to interact with dextromethorphan and cause serotonin syndrome, such as monoamine oxidase inhibitors or selective serotonin reuptake inhibitors, poison center-initiated follow-up every 2 hours for 8 hours is recommended (Grade D). 6) Patients who are asymptomatic and more than 4 hours have elapsed since the time of ingestion can be observed at home (Grade C). 7) Do not induce emesis (Grade D). 8) Do not use activated charcoal at home. Activated charcoal can be administered to asymptomatic patients who have ingested overdoses of dextromethorphan within the preceding hour. Its administration, if available, should only be carried out by health professionals and only if no contraindications are present. Do not delay transportation in order to administer activated charcoal (Grade D). 9) For patients who have ingested dextromethorphan and are sedated or comatose, naloxone, in the usual doses for treatment of opioid overdose, can be considered for prehospital administration, particularly if the patient has respiratory depression (Grade C). 10) Use intravenous benzodiazepines for seizures and benzodiazepines and external cooling measures for hyperthermia (>104 degrees F, >40 degrees C) for serotonin syndrome. This should be done in consultation with and authorized by EMS medical direction, by a written treatment protocol or policy, or with direct medical oversight (Grade C). 11) Carefully ascertain by history whether other drugs, such as acetaminophen, were involved in the incident and assess the risk for toxicity or for a drug interaction.
1)描述管理右美沙芬摄入的过程;2)确定管理右美沙芬摄入病例的关键决策要素;3)提供反映当前知识水平的清晰实用建议;4)确定研究需求。本指南仅适用于单独摄入右美沙芬的情况。同时摄入其他物质可能需要根据这些物质的联合毒性制定不同的转诊和管理建议。本指南基于对当前科学和临床信息的评估。专家共识小组认识到,具体的患者护理决策可能与本指南不一致,在考虑所有相关情况后,由患者和提供护理的卫生专业人员自行决定。本指南不能替代临床判断。建议等级标注在括号内。1)所有有自杀意图、故意滥用或疑似有恶意意图(如虐待或忽视儿童)的患者应转诊至急诊科(D级)。2)急性摄入右美沙芬后出现超过轻度症状(如偶尔呕吐或嗜睡[轻度镇静,对说话声音或轻触有反应])的患者应转诊至急诊科(C级)。3)摄入5 - 7.5 mg/kg的患者应在摄入后约每2小时接受中毒控制中心发起的随访,最长持续4小时。如果出现超过轻度的症状,应转诊至急诊科(D级)。4)摄入超过7.5 mg/kg的患者应转诊至急诊科进行评估(C级)。5)如果患者正在服用其他可能与右美沙芬相互作用并导致5-羟色胺综合征的药物,如单胺氧化酶抑制剂或选择性5-羟色胺再摄取抑制剂,建议中毒控制中心每2小时发起随访,持续8小时(D级)。6)无症状且自摄入时间起已过去4小时以上的患者可在家中观察(C级)。7)不要催吐(D级)。8)不要在家中使用活性炭。对于在过去1小时内摄入过量右美沙芬的无症状患者,可给予活性炭。如有条件,活性炭的给予应由卫生专业人员进行,且仅在无禁忌证时进行。不要为了给予活性炭而延迟转运(D级)。9)对于摄入右美沙芬且镇静或昏迷的患者,可考虑在院前给予纳洛酮,剂量为治疗阿片类药物过量的常用剂量,特别是如果患者有呼吸抑制(C级)。10)对于5-羟色胺综合征的癫痫发作,使用静脉注射苯二氮䓬类药物;对于体温过高(>104华氏度,>40摄氏度),使用苯二氮䓬类药物和外部降温措施。这应在与紧急医疗服务(EMS)医疗指导协商并获得其授权后进行,可通过书面治疗方案或政策,或在直接医疗监督下进行(C级)。11)通过病史仔细确定事件中是否涉及其他药物,如对乙酰氨基酚,并评估毒性风险或药物相互作用风险。